Article thumbnail

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6

By J P B O'Connor, C J Rose, A Jackson, Y Watson, S Cheung, F Maders, B J Whitcher, C Roberts, G A Buonaccorsi, G Thompson, A R Clamp, G C Jayson and G J M Parker
Topics: Molecular Diagnostics
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:3137409
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2011). Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response?
  2. (2000). Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
  3. (2008). Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography.
  4. (2009). Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps.